Open Your Free Demat Account
Access Research Backed Stock Recommendations
Prasol Chemicals Limited manufactures acetone and phosphorous-based specialty chemicals, along with other customised chemical products, for customers across pharmaceuticals, agrochemicals and other industries. The company reported FY2026 revenue of ₹1,237.85 crore and profit after tax of ₹83.12 crore, up from ₹18.13 crore in FY2024.
At the same time, investors may weigh the company's dependence on two manufacturing facilities and imported raw materials against its revenue growth and long-standing customer relationships before evaluating the IPO.
India's specialty chemicals market expanded from ₹2,240 billion in FY2019 to ₹5,563 billion in FY2026. Prasol Chemicals Limited operates in this market segment as a manufacturer of acetone and phosphorus-based specialty chemicals. (Source: RHP, citing CARE Report). The company has filed its Red Herring Prospectus (RHP) with the Securities and Exchange Board of India (SEBI) ahead of the Prasol Chemicals IPO.
The RHP discloses how the company generates revenue, its planned use of issue proceeds, and the risks tied to its operations. Prasol Chemicals IPO details form part of a wider set of Upcoming IPO filings in the specialty chemicals space.
The table below highlights the key details of the Prasol Chemicals IPO available in the RHP.
| Particulars | Details |
|---|---|
| IPO Type | 100% Book Built Offer |
| IPO Open Date | September 8, 2026 |
| IPO Close Date | September 10, 2026 |
| Face Value | ₹2 per equity share |
| Price Band | ₹643 to ₹676 per share |
| Lot Size | 22 shares |
| Fresh Issue | 11,83,431 shares (agg. up to ₹80 Cr) |
| Offer for Sale | 62,13,006 shares of ₹2 (agg. up to ₹420 Cr) |
| Total Issue Size | 73,96,437 shares (agg. up to ₹500 Cr) |
| Listing Exchange | NSE and BSE |
The Offer combines a Fresh Issue of up to ₹80 crore with an Offer for Sale of up to ₹420 crore by the promoter and promoter group selling shareholders, and the company will not receive proceeds from the Offer for Sale.
Prasol Chemicals Limited holds Corporate Identity Number U99999MH1992PLC065026 and is registered in Navi Mumbai, Maharashtra. The company was incorporated in 1992 and has operated in the specialty chemicals industry for more than 33 years.
Ten promoters lead the company, including Nishith Rajnikant Shah, Gaurang Natwarlal Parikh and Dhaval Nalin Parikh, alongside seven other promoter shareholders named in the RHP.
Prasol manufactures acetone and phosphorous-based specialty chemicals, along with other specialty chemicals built on complex, differentiated chemistry. Its portfolio spanned more than 150 products across 1,618 customers in 56 countries as of Fiscal 2026 (Source: RHP, citing CARE Report).
The product portfolio splits into three groups:
21 acetone-based specialty chemicals, including diacetone alcohol and isophorone
53 phosphorous-based specialty chemicals, including phosphorous pentasulphide and polyphosphoric acid
76 other specialty chemicals, including surfactants, performance additives, ethers and esters
Prasol recorded the highest acetone import volumes among Indian companies between calendar years 2022 and 2025, and remained the only Indian manufacturer of isophorone over the same period (Source: RHP, citing CARE Report).
Acetone based specialty chemicals contributed 42.75% to the revenue from operations for FY2026, phosphorous based chemicals contributed 38.30% and the remaining 18.33% came from other specialty chemicals.
Revenue from Operations grew from ₹887.56 crore in FY2024 to ₹1,237.85 crore in FY2026, a CAGR of 18.55%. Exports contributed 27.29% of revenue in FY2026, spread across 56 countries.
The global specialty chemicals market was valued at $721 billion in CY2019 and is projected to reach $1,240 billion in CY2025 at a CAGR of 9.5%. It is further projected to reach $1,748 billion in CY2029 (Source: RHP, CARE Report).
The Indian acetone derivatives market grew from ₹35.6 billion in FY2019 to ₹83.9 billion in FY2026, while the phosphorus derivatives market is projected to grow from roughly ₹998 billion in FY2024 to ₹1,625 billion by FY2029 (Source: RHP, citing CARE Report).
The Indian acetone derivatives market grew from ₹35.6 billion in FY2019 to ₹83.9 billion in FY2026, while the phosphorus derivatives market is projected to grow from roughly ₹998 billion in FY2024 to ₹1,625 billion by FY2029 (Source: RHP, citing CARE Report).
Specialty chemicals earn their pricing power the way a tailor does. Customers pay for a formulation cut to their exact process, not a generic batch pulled off a shelf.
The CARE Report cited throughout this section was commissioned and paid for by Prasol itself, standard practice for RHP industry sections across Indian IPOs. That funding arrangement does not necessarily change the underlying data, but it is a detail worth knowing before treating any single figure as independent.
The table below summarises Prasol Chemicals Limited's financial performance over the last three years, based on the Restated Financial Information in the RHP.
| Financials (₹ crore) | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Revenue from Operations | 1,237.85 | 1,015.54 | 887.56 |
| EBITDA | 139.32 | 87.77 | 60.53 |
| PAT | 83.12 | 43.57 | 18.13 |
| Total Assets | 839.28 | 723.09 | 626.36 |
| Net Worth | 448.51 | 367.46 | 325.84 |
Revenue from Operations and profit both rose every year, with profit after tax up from ₹18.13 crore in FY2024 to ₹83.12 crore in FY2026. Net Worth increased from ₹325.84 crore to ₹448.51 crore over the same period.
The company's portfolio spanned more than 150 specialty chemical products as of June 30, 2026, serving five application industries from performance chemicals to home and personal care. That range reduces dependence on demand from any single end market (Source: RHP, citing CARE Report).
Prasol served 1,618 customers in FY2026 including Coromandel International, Lubrizol India and Alembic Pharmaceuticals. Revenue from operations of top 10 customers stood at 23.68% in FY2026 as against 18.46% in FY2024.
The board and senior management have decades of experience across finance, banking and chemicals manufacturing, backed by a succession plan mentoring junior directors and managers. The company has been in operation for more than 33 years under the same promoter group.
Revenue from Operations grew from ₹887.56 crore in FY2024 to ₹1,237.85 crore in FY2026, alongside a net debt-to-equity ratio of 0.19 times as of March 31, 2026. Acuite Ratings reaffirmed the company's long-term borrowing rating at ACUITE A+.
Both manufacturing facilities sit in Khopoli and Mahad, Maharashtra. The Maharashtra Pollution Control Board has issued closure directions and show-cause notices to the company in the past over compliance matters.
Certain raw materials, byproducts and finished goods used in production are corrosive and flammable. Facilities have recorded past incidents, including a fire at the Khopoli plant. Any repeat would disrupt operations.
The company's top 10 customers contributed 23.68% of revenue from operations in FY2026, up from 18.46% in FY2024. Losing one of these accounts would affect a growing share of revenue.
Imports made up 65.96% of raw material procurement costs in FY2026, sourced from China, Thailand, Korea and other countries. Currency swings or import restrictions would raise input costs directly.
Demand for Prasol's chemicals depends on the commercial success of customers' end products, from pharmaceuticals to agrochemicals. A slowdown in any of these end markets would affect orders indirectly.
Manufacturing chemicals requires ongoing approvals, licences and registrations from multiple authorities. Delay or failure to renew any of these would affect production continuity.
Before evaluating the IPO, investors may consider the following factors:
The company's dependence on two manufacturing facilities in Maharashtra
History of regulatory notices and closure directions from pollution control authorities
Customer concentration among the top ten accounts
Dependence on imported raw materials for acetone and phosphorous-based production
Growth in revenue and profit margin relative to the specialty chemicals sector
Regulatory approvals and licensing requirements across manufacturing operations
Revenue split across acetone-based, phosphorous-based and other specialty chemicals
Undisclosed price band and lot size as of the RHP filing date
These factors should be considered alongside the complete risk disclosures and financial information provided in the RHP.
Disclaimer :
Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading